Your browser doesn't support javascript.
loading
Show: 20 | 50 | 100
Results 1 - 20 de 29
Filter
1.
Braz. J. Pharm. Sci. (Online) ; 58: e19832, 2022. tab, graf
Article in English | LILACS | ID: biblio-1394063

ABSTRACT

Abstract Medication reconciliation is a strategy to minimize medication errors at the transition points of care. This study aimed to demonstrate the effectiveness of medication reconciliation in identifying and resolving drug discrepancies in the admission of adult patients to a university hospital. The study was carried out in a 300-bed large general public hospital, in which a reconciled list was created between drugs prescribed at admission and those used at pre-admission, adapting prescriptions from the pharmacotherapeutic guidelines of the hospital studied and the patients' clinical conditions. One hundred seven patients were included, of which 67,3% were women, with a mean age of 56 years. Two hundred twenty-nine discrepancies were found in 92 patients; of these, 21.4% were unintentional in 31.8% of patients. The pharmacist performed 49 interventions, and 47 were accepted. Medication omission was the highest occurrence (63.2%), followed by a different dose (24.5%). Thirteen (26.5%) of the 49 unintentional discrepancies included high-alert medications according to ISMP Brazil classification. Medication reconciliation emerges as an important opportunity for the review of pharmacotherapy at transition points of care, based on the high number of unintentional discrepancies identified and resolved. During the drug reconciliation process, the interventions prevented the drugs from being misused or omitted during the patient's hospitalization and possibly after discharge.


Subject(s)
Humans , Male , Female , Adolescent , Adult , Middle Aged , Aged , Aged, 80 and over , Young Adult , Medication Reconciliation/methods , Hospitals, University , Pharmaceutical Services , Pharmaceutical Preparations/administration & dosage , Prescriptions/standards , Patient Safety , Medication Errors/prevention & control
2.
Braz. J. Pharm. Sci. (Online) ; 57: e181060, 2021. tab
Article in English | LILACS | ID: biblio-1350238

ABSTRACT

The purpose of this study is to describe the frequency of potential drug prescribing omissions (PPOs) for elderly patients at the time of hospital discharge and to compare the frequency PPOs among different medical specialities. This cross-sectional study examined data from elderly patients when they were admitted for >24 h to a northeastern Brazil teaching hospital during June-December 2016. Were included in the study 227 patients, of whom 36.9% had at least one PPO. The highest number of PPOs was identified among those with at least 5 prescribed drugs. In total, 153 PPOs were identified at hospital discharge. In most cases (78.4%), patients were not evaluated by the specialist physician.The most commonly identified PPOs on discharge were: the omission of statin therapy in cases of diabetes mellitus plus one or more cardiovascular-associated factor; calcium and vitamin D supplements in patients with known osteoporosis; and angiotensin converting enzyme inhibitors in cases of chronic heart failure. The results of this study suggest that the frequency of prescribing omissions PPOs during patient discharge was high. This can be avoided by the careful evaluation by prescribers with experience in certain specialties where several prescribed omissions would be common.


Subject(s)
Humans , Male , Female , Middle Aged , Aged , Aged, 80 and over , Patient Discharge/standards , Patient Discharge/statistics & numerical data , Physicians , Drug Prescriptions/standards , Prescription Drug Misuse/statistics & numerical data , Potentially Inappropriate Medication List/classification , Health Services for the Aged/supply & distribution , Health Services for the Aged/ethics , Hospitals , Cross-Sectional Studies , Diabetes Mellitus/drug therapy , Patient Safety/standards , Geriatrics/classification
3.
Int J Clin Pharm ; 40(6): 1596-1600, 2018 Dec.
Article in English | MEDLINE | ID: mdl-30242588

ABSTRACT

Background Potentially inappropriate prescribing for older people has become a global concern, although few researchers have analyzed potential prescribing omissions for this population. Objective This study aimed to compare the frequency of potential prescribing omissions for elderly patients at their admission to and discharge from a university hospital in northeast Brazil, using the validated and adapted Brazilian START criteria. Setting A university hospital in northeast Brazil. Methods This cross-sectional study examined data from patients who were ≥ 60 years old when they were admitted for > 24 h to a northeastern Brazil teaching hospital during June-December 2016. Main outcome measure Frequency of potential prescribing omissions for elderly patients at their admission to and discharge. Results Data from 227 patients were included. The mean patient age was 71 ± 8.23 years. The patients included 131 women (57.7%), and 176 patients (77.5%) presented with a Charlson Comorbidity Index of ≥ 3. Based on the START criteria, the frequency of potential prescribing omissions was 44.1% (100/227) at the admission and decreased to 39.6% (90/227) at the discharge. The most common potential omissions at the admission were beta-blockers in cases of stable chronic angina, and angiotensin converting enzyme inhibitors or angiotensin receptor blockers in cases of diabetic nephropathy or renal dysfunction. Conclusion The prevalence of potential prescribing omissions among elderly patients remained relatively high at their discharge from a northeastern Brazilian university hospital. The START criteria could be a useful tool to optimize the clinical management of the elderly.


Subject(s)
Drug Prescriptions/statistics & numerical data , Inappropriate Prescribing/statistics & numerical data , Medication Errors/statistics & numerical data , Aged , Aged, 80 and over , Brazil/epidemiology , Cross-Sectional Studies , Female , Hospitals, University/statistics & numerical data , Humans , Male , Middle Aged , Patient Admission , Patient Discharge , Prevalence
4.
Article in English | MEDLINE | ID: mdl-29972466

ABSTRACT

In 2012, the first-generation protease inhibitors telaprevir (TVR) and boceprevir (BOC) were introduced in the Brazilian health system for treatment of chronic hepatitis C, after their approval by the National Committee for Health Technology Incorporation (CONITEC). However, these medicines were discontinued in 2015. The short period of use in therapy and their high cost require a discussion about the consequences for patients and for the health system of the early incorporation of new therapies. The article presents a qualitative analysis of the incorporation process of both medications in Brazil and the results of a multicenter study that included patients treated with BOC or TVR between January 2011 and December 2015 in five Brazilian cities. The study included 855 patients (BOC: n=247) and (TVR: n=608). The document analysis showed that CONITEC's decision to incorporate BOC and TVR was based on results of phase III clinical trials that compared sustained virologic response (SVR) rates of patients treated with BOC and TVR with rates of those that received placebo. However, these studies included a low percentage of cirrhotic patients. The SVR rates observed in this multicenter study were worse than clinical trials pointed out (BOC: 45.6%; TVR: 51.8%), but similar to those achieved with previously adopted therapies. The discontinuation rate due to adverse events was (BOC: 15.4%; TVR: 12.7%). Based on these unsatisfactory results, the study brings a discussion that goes beyond the therapy outcomes, exploring the incorporation of these high-cost medicines and the related decision-making process, contributing to future decisions in medicine policies and in the treatment of chronic hepatitis C.


Subject(s)
Antiviral Agents/administration & dosage , Hepatitis C, Chronic/drug therapy , Oligopeptides/administration & dosage , Proline/analogs & derivatives , Protease Inhibitors/administration & dosage , Antiviral Agents/economics , Clinical Protocols , Decision Making , Drug Therapy, Combination , Female , Genotype , Hepacivirus/genetics , Hepatitis C, Chronic/economics , Humans , Interferon alpha-2 , Interferon-alpha/administration & dosage , Male , Middle Aged , Oligopeptides/economics , Polyethylene Glycols/administration & dosage , Proline/administration & dosage , Proline/economics , Protease Inhibitors/economics , Recombinant Proteins/administration & dosage , Retrospective Studies , Ribavirin/administration & dosage
5.
Braz. J. Pharm. Sci. (Online) ; 54(3): e17418, 2018.
Article in English | LILACS | ID: biblio-974403

ABSTRACT

The consumption of botanicals for therapeutic purposes has increased significantly in recent years. Drug-induced liver disease (DILI) is a frequent cause of acute liver injury, around 50% in the United States, and about 1% is secondary to the use of phytotherapeuticals and herbal supplies. Ruellia bahiensis, a plant species of the Acanthaceae family, is a tropical plant distributed in Northeastern Brazil. In folk medicine in the state of Bahia, the species is known as "mãe-boa" and is commonly used. L.S.S, a 23-year old, female, patient was admitted at University Hospital of Bahia-Brazil with signs and symptoms of acute hepatitis. She had made daily use of an herbal supply popularly known as "mãe-boa" for at least two years prescribed by a physician. Diagnostic investigation was negative for viral and autoimmune hepatitis, leptospirosis, dengue, and CMV (cytomegalovirus). The patient had to undergo liver transplantation. Explant revealed massive hepatic necrosis. According to histological findings, and after exclusion of other etiologies, liver damage was assigned to herbal supply. The prolonged use of Ruellia bahiensis infusions may have caused the liver dysfunction.


Subject(s)
Plant Poisoning , Liver Failure, Acute/complications , Liver Transplantation , Acanthaceae/classification , Phytotherapeutic Drugs , Chemical and Drug Induced Liver Injury/classification
6.
Sao Paulo Med J ; 135(2): 92-99, 2017.
Article in English | MEDLINE | ID: mdl-28443947

ABSTRACT

CONTEXT AND OBJECTIVE:: In 2004, the Brazilian National Health Surveillance Agency (Agência Nacional de Vigilância Sanitária, ANVISA) published a resolution establishing guidelines for albumin use. Although the published data do not indicate any definitive conclusions about the benefits of albumin use in patients with nephrotic syndrome (NS), the guidelines recommend this procedure only in cases of edema that is refractory to use of diuretics. The aim here was to analyze albumin use among patients with nephrotic syndrome. DESIGN AND SETTING:: Pharmacoeconomic study conducted in four large public referral hospitals for nephrology services in northeastern Brazil. METHOD:: Cost-effectiveness and cost-utility economic evaluations were performed on a concurrent cohort of patients with nephrotic syndrome, who were divided into two groups according to compliance or noncompliance with the guidelines. Quality-of-life data were obtained from the SF36 and CHQ-PF50 questionnaires. RESULTS:: This study enrolled 109 patients (60% adults and 56% women); 41.3% were using albumin in accordance with the guidelines. The weight, diuresis and fluid balance parameters were more cost-effective for patients who adhered to the guidelines. Regarding days of hospitalization avoided, the incremental ratio showed a daily cost of R$ 55.33, and guideline-compliant patients were hospitalized for five days or fewer. The quality of life improved by 8%, and savings of R$ 3,458.13/QALY (quality-adjusted life year) for the healthcare system were generated through guideline compliance. CONCLUSION:: The economic analyses of this study demonstrated that there were greater cost benefits for patients whose treatment followed the guidelines.


Subject(s)
Albumins/therapeutic use , Cost-Benefit Analysis/economics , Economics, Pharmaceutical , Guideline Adherence/economics , Nephrotic Syndrome/drug therapy , Nephrotic Syndrome/economics , Adolescent , Adult , Brazil , Child , Cohort Studies , Female , Hospitalization/economics , Hospitals, Public , Humans , Male , Middle Aged , Quality of Life , Young Adult
7.
São Paulo med. j ; 135(2): 92-99, Mar.-Apr. 2017. tab, graf
Article in English | LILACS | ID: biblio-846298

ABSTRACT

ABSTRACT CONTEXT AND OBJECTIVE: In 2004, the Brazilian National Health Surveillance Agency (Agência Nacional de Vigilância Sanitária, ANVISA) published a resolution establishing guidelines for albumin use. Although the published data do not indicate any definitive conclusions about the benefits of albumin use in patients with nephrotic syndrome (NS), the guidelines recommend this procedure only in cases of edema that is refractory to use of diuretics. The aim here was to analyze albumin use among patients with nephrotic syndrome. DESIGN AND SETTING: Pharmacoeconomic study conducted in four large public referral hospitals for nephrology services in northeastern Brazil. METHOD: Cost-effectiveness and cost-utility economic evaluations were performed on a concurrent cohort of patients with nephrotic syndrome, who were divided into two groups according to compliance or noncompliance with the guidelines. Quality-of-life data were obtained from the SF36 and CHQ-PF50 questionnaires. RESULTS: This study enrolled 109 patients (60% adults and 56% women); 41.3% were using albumin in accordance with the guidelines. The weight, diuresis and fluid balance parameters were more cost-effective for patients who adhered to the guidelines. Regarding days of hospitalization avoided, the incremental ratio showed a daily cost of R$ 55.33, and guideline-compliant patients were hospitalized for five days or fewer. The quality of life improved by 8%, and savings of R$ 3,458.13/QALY (quality-adjusted life year) for the healthcare system were generated through guideline compliance. CONCLUSION: The economic analyses of this study demonstrated that there were greater cost benefits for patients whose treatment followed the guidelines.


RESUMO CONTEXTO E OBJETIVO: Em 2004, a Agência Nacional de Vigilância Sanitária (ANVISA) publicou uma resolução que estabelece diretrizes para o uso de albumina. Embora os dados publicados não indiquem conclusões definitivas sobre os benefícios do uso de albumina em pacientes com síndrome nefrótica (SN), a diretriz recomenda o procedimento apenas em casos de edema refratário ao uso de diuréticos. O objetivo aqui foi analisar o uso de albumina em pacientes com síndrome nefrótica. TIPO DE ESTUDO E LOCAL: Estudo farmacoeconômico realizado em quatro grandes hospitais públicos de referência em serviços de nefrologia no nordeste do Brasil. MÉTODO: Foram realizadas avaliações econômicas do tipo custo-efetividade e custo-utilidade em uma coorte concorrente de pacientes com síndrome nefrótica, divididos em dois grupos de acordo com o cumprimento ou descumprimento das diretrizes. Dados de qualidade de vida foram obtidos a partir dos questionários SF36 e CHQ-PF50. RESULTADOS: Este estudo incluiu 109 pacientes (60% adultos e 56% mulheres); 41,3% estavam usando albumina conforme as diretrizes. Os parâmetros de peso, diurese e balanço hídrico foram mais custo-efetivos para pacientes que aderiram às diretrizes. Quanto a dias de internação evitados, a razão incremental mostrou um custo diário de R$ 55,33, sendo que os pacientes que seguiram as diretrizes ficaram cinco dias a menos internados. A qualidade de vida melhorou 8%, gerando economia de R$ 3,458.13/QALY (quality-adjusted life year) para o sistema de saúde por meio do cumprimento das diretrizes. CONCLUSÃO: As análises econômicas deste estudo demonstraram maiores benefícios em termos de custo para os pacientes cujo tratamento seguiu as diretrizes.


Subject(s)
Humans , Male , Female , Child , Adolescent , Adult , Middle Aged , Young Adult , Cost-Benefit Analysis/economics , Economics, Pharmaceutical , Guideline Adherence/economics , Albumins/therapeutic use , Nephrotic Syndrome/economics , Nephrotic Syndrome/drug therapy , Quality of Life , Brazil , Cohort Studies , Hospitalization/economics , Hospitals, Public
8.
São Paulo med. j ; 134(1): 20-27, Jan.-Feb. 2016. tab
Article in English | LILACS | ID: lil-777458

ABSTRACT

CONTEXT AND OBJECTIVE: Non-treatment of diseases or clinical conditions has been considered to constitute omission of care in several countries. The aim of the present study was to develop a transcultural adaptation of the Screening Tool to Alert Doctors to the Right Treatment (START) to Brazilian Portuguese and to validate the tool's content. DESIGN AND SETTING: Cultural adaptation and validation of the START criteria using the Delphi consensus technique. METHOD: START was translated from its original language into Brazilian Portuguese, followed by back-translation and validation by means of the modified Delphi technique. For this, an electronic form was developed and sent to 20 experts, who were asked to use a Likert scale to assess the statements included in START, in relation to their pertinence to Brazilian realities. All of the statements that exhibited mean scores greater than 4.0 were considered to have attained consensus. The experts' identities were kept confidential throughout the validation process. RESULTS: In the first phase of the validation process, 63.6% (14/22) of the statements in START attained consensus. The remaining statements were returned to the experts so that they could have the opportunity to review their comments and statements and to assess them again, based on the Likert scale used earlier. In this phase, 100% of the START instrument attained consensus. CONCLUSION: The content of START was entirely validated for Brazil, with all of the original criteria maintained.


RESUMO CONTEXTO E OBJETIVO: O não tratamento de doenças ou condições clínicas tem sido apontado como omissão no cuidado em diversos países. O objetivo deste estudo foi realizar a adaptação transcultural para o português brasileiro e sua validação de conteúdo do questionário START (Screening Tool to Alert Doctors to the Right Treatment). TIPO DE ESTUDO E LOCAL: Adaptação cultural e validação dos critérios START através da técnica de consenso Delphi. MÉTODO: O START foi submetido à tradução da língua original para o Português (Brasil), tradução reversa e validação de conteúdo por meio da técnica Delphi modificada. Para isso, um formulário eletrônico foi desenvolvido e enviado a 20 especialistas para o julgamento das proposições presentes na ferramenta START conforme sua pertinência para a realidade brasileira, utilizando uma escala de Likert. Foram consideradas consensuais todas as proposições que apresentaram média superior a 4,0. A identificação de cada especialista foi mantida em confidencialidade durante o todo o processo. RESULTADOS: Na primeira fase da validação, foi obtido consenso em 63,6% (14/22) das proposições contidas na ferramenta START. As proposições não consensuais foram reencaminhadas para os especialistas, que tiveram a oportunidade de rever seus comentários e proposições e julgá-las com base na escala de Likert utilizada previamente. Nessa fase, foi obtido consenso em 100% do instrumento START. CONCLUSÃO: O conteúdo do START foi validado para o Brasil na sua totalidade, com todos os critérios originais mantidos.


Subject(s)
Humans , Aged , Drug Prescriptions/standards , Translations , Cross-Cultural Comparison , Surveys and Questionnaires , Peer Group , Brazil , Delphi Technique , Language
9.
Sao Paulo Med J ; 134(1): 20-7, 2016.
Article in English | MEDLINE | ID: mdl-26786612

ABSTRACT

CONTEXT AND OBJECTIVE: Non-treatment of diseases or clinical conditions has been considered to constitute omission of care in several countries. The aim of the present study was to develop a transcultural adaptation of the Screening Tool to Alert Doctors to the Right Treatment (START) to Brazilian Portuguese and to validate the tool's content. DESIGN AND SETTING: Cultural adaptation and validation of the START criteria using the Delphi consensus technique. METHOD: START was translated from its original language into Brazilian Portuguese, followed by back-translation and validation by means of the modified Delphi technique. For this, an electronic form was developed and sent to 20 experts, who were asked to use a Likert scale to assess the statements included in START, in relation to their pertinence to Brazilian realities. All of the statements that exhibited mean scores greater than 4.0 were considered to have attained consensus. The experts' identities were kept confidential throughout the validation process. RESULTS: In the first phase of the validation process, 63.6% (14/22) of the statements in START attained consensus. The remaining statements were returned to the experts so that they could have the opportunity to review their comments and statements and to assess them again, based on the Likert scale used earlier. In this phase, 100% of the START instrument attained consensus. CONCLUSION: The content of START was entirely validated for Brazil, with all of the original criteria maintained.


Subject(s)
Cross-Cultural Comparison , Drug Prescriptions/standards , Surveys and Questionnaires , Translations , Aged , Brazil , Delphi Technique , Humans , Language , Peer Group
10.
J. bras. pneumol ; 41(6): 496-501, Nov.-Dec. 2015. tab
Article in Portuguese | LILACS | ID: lil-769781

ABSTRACT

ABSTRACT OBJECTIVE: To identify, characterize, and quantify associations of various factors with quality of life (QoL) in patients with asthma, according to the pharmacotherapy employed. METHODS: This was a cross-sectional study involving 49 patients (≥ 18 years of age) with severe uncontrolled or refractory asthma treated at a specialized outpatient clinic of the Brazilian Unified Health Care System, regularly using high doses of inhaled corticosteroids (ICs) or other medications, and presenting comorbidities. At a single time point, QoL was assessed with the Asthma Quality of Life Questionnaire (AQLQ). The overall AQLQ score and those of its domains were correlated with demographic variables (gender and age); Asthma Control Questionnaire score; pharmacotherapy (initial IC dose, inhaler devices, and polytherapy); and comorbidities. RESULTS: Better AQLQ scores were associated with asthma control-overall (OR = 0.38; 95% CI: 0.004-0.341; p < 0.001), "symptoms" domain (OR = 0.086; 95% CI: 0.016-0.476; p = 0.001), and "emotional function" domain (OR = 0.086; 95% CI: 0.016-0.476; p = 0.001)-and with IC dose ≤ 800 µg-"activity limitation" domain (OR = 0.249; 95% CI: 0.070-0.885; p = 0.029). Worse AQLQ scores were associated with polytherapy-"activity limitation" domain (OR = 3.651; 95% CI: 1.061-12.561; p = 0.036)-and number of comorbidities ≤ 5-"environmental stimuli" domain (OR = 5.042; 95% CI: 1.316-19.317; p = 0.015). CONCLUSIONS: Our results, the importance of this issue, and the lack of studies taking pharmacotherapy into consideration warrant longitudinal studies to establish a causal relationship between the identified factors and QoL in asthma patients.


RESUMO OBJETIVO: Identificar, caracterizar e medir a associação de fatores relacionados à qualidade de vida (QV) de pacientes asmáticos sob a perspectiva da farmacoterapia. MÉTODOS: Estudo de corte transversal com 49 pacientes (≥ 18 anos) portadores de asma grave não controlada ou asma refratária, atendidos em um ambulatório especializado do Sistema Único de Saúde, em uso regular de altas doses de corticoides inalatórios (CIs) e/ou de diversos medicamentos e com comorbidades. Obtiveram-se as medidas de QV através da aplicação do questionário Asthma Quality of Life Questionnaire (AQLQ) num único momento. O escore global e dos domínios do AQLQ foram relacionados com variáveis demográficas (gênero e idade), escore do Asthma Control Questionnaire, terapia medicamentosa (dose inicial de CI, dispositivos inalatórios e politerapia) e comorbidades. RESULTADOS: Melhores escores do AQLQ associaram-se com asma controlada - escore global (OR = 0,38; IC95%: 0,004-0,341; p < 0,001) e domínios "sintomas" (OR = 0,086; IC95%: 0,016-0,476; p = 0,001) e "função emocional" (OR = 0,086; IC95%: 0,016-0,476; p = 0,001) - e com dose de CI ≤ 800 µg - domínio "limitação de atividades" (OR = 0,249; IC95%: 0,070-0,885; p = 0,029). Piores escores do AQLQ correlacionaram-se com politerapia - domínio "limitação de atividades" (OR = 3,651; IC95%: 1,061-12,561; p = 0,036) - e com número de comorbidades ≤ 5 - domínio "estímulo ambiental" (OR = 5,042; IC95%: 1,316-19,317; p = 0,015). CONCLUSÕES: Nossos resultados, a importância do tema, e a escassez de estudos sob a perspectiva da farmacoterapia apontam a necessidade da realização de estudos longitudinais para se estabelecer uma relação de causalidade entre os fatores identificados e a QV em pacientes com asma.


Subject(s)
Female , Humans , Male , Middle Aged , Adrenal Cortex Hormones/therapeutic use , Anti-Asthmatic Agents/therapeutic use , Asthma/drug therapy , Asthma/psychology , Medication Therapy Management , Quality of Life , Brazil , Cross-Sectional Studies , Surveys and Questionnaires
11.
J Bras Pneumol ; 41(6): 496-501, 2015.
Article in English, Portuguese | MEDLINE | ID: mdl-26785957

ABSTRACT

OBJECTIVE: To identify, characterize, and quantify associations of various factors with quality of life (QoL) in patients with asthma, according to the pharmacotherapy employed. METHODS: This was a cross-sectional study involving 49 patients (≥ 18 years of age) with severe uncontrolled or refractory asthma treated at a specialized outpatient clinic of the Brazilian Unified Health Care System, regularly using high doses of inhaled corticosteroids (ICs) or other medications, and presenting comorbidities. At a single time point, QoL was assessed with the Asthma Quality of Life Questionnaire (AQLQ). The overall AQLQ score and those of its domains were correlated with demographic variables (gender and age); Asthma Control Questionnaire score; pharmacotherapy (initial IC dose, inhaler devices, and polytherapy); and comorbidities. RESULTS: Better AQLQ scores were associated with asthma control--overall (OR = 0.38; 95% CI: 0.004-0.341; p < 0.001), "symptoms" domain (OR = 0.086; 95% CI: 0.016-0.476; p = 0.001), and "emotional function" domain (OR = 0.086; 95% CI: 0.016-0.476; p = 0.001)-and with IC dose ≤ 800 µg--"activity limitation" domain (OR = 0.249; 95% CI: 0.070-0.885; p = 0.029). Worse AQLQ scores were associated with polytherapy--"activity limitation" domain (OR = 3.651; 95% CI: 1.061-12.561; p = 0.036)-and number of comorbidities ≤ 5--"environmental stimuli" domain (OR = 5.042; 95% CI: 1.316-19.317; p = 0.015). CONCLUSIONS: Our results, the importance of this issue, and the lack of studies taking pharmacotherapy into consideration warrant longitudinal studies to establish a causal relationship between the identified factors and QoL in asthma patients.


Subject(s)
Adrenal Cortex Hormones/therapeutic use , Anti-Asthmatic Agents/therapeutic use , Asthma/drug therapy , Asthma/psychology , Medication Therapy Management , Quality of Life , Brazil , Cross-Sectional Studies , Female , Humans , Male , Middle Aged , Surveys and Questionnaires
12.
PLoS One ; 9(12): e115491, 2014.
Article in English | MEDLINE | ID: mdl-25531902

ABSTRACT

OBJECTIVES: To compare drugs prescribed on hospital admission with the list of drugs taken prior to admission for adult patients admitted to a cardiology unit and to identify the role of a pharmacist in identifying and resolving medication discrepancies. METHOD: This study was conducted in a 300 bed university hospital in Brazil. Clinical pharmacists taking medication histories and reconciling medications prescribed on admission with a list of drugs used prior to admission. Discrepancies were classified as justified (e.g., based on the pharmacotherapeutic guidelines of the hospital studied) or unintentional. Treatments were reviewed within 48 hours following hospitalization. Unintentional discrepancies were further classified according to the categorization of medication error severity. Pharmacists verbally contacted the prescriber to recommend actions to resolve the discrepancies. RESULTS: A total of 181 discrepancies were found in 50 patients (86%). Of these discrepancies, 149 (82.3%) were justified changes to the patient's home medication regimen; however, 32 (17.7%) discrepancies found in 24 patients were unintentional. Pharmacists made 31 interventions and 23 (74.2%) were accepted. Among unintentional discrepancies, the most common was a different medication dose on admission (42%). Of the unintentional discrepancies 13 (40.6%) were classified as error without harm, 11 (34.4%) were classified as error without harm but which could affect the patient and require monitoring, 3 (9.4%) as errors could have resulted in harm and 5 (15.6%) were classified as circumstances or events that have the capacity to cause harm. CONCLUSION: The results revealed a high number of unintentional discrepancies and the pharmacist can play an important role by intervening and correcting medication errors at a hospital cardiology unit.


Subject(s)
Cardiovascular Diseases/drug therapy , Hospitalization/statistics & numerical data , Medication Errors/prevention & control , Medication Reconciliation/organization & administration , Pharmacists/organization & administration , Adolescent , Adult , Aged , Brazil , Communication , Female , Follow-Up Studies , Hospitals, University , Humans , Male , Medical History Taking/statistics & numerical data , Medication Errors/statistics & numerical data , Medication Reconciliation/standards , Middle Aged , Patient Admission , Patient Discharge , Patient Safety , Prescription Drugs/administration & dosage , Prognosis , Young Adult
13.
J Antimicrob Chemother ; 69(7): 1954-9, 2014 Jul.
Article in English | MEDLINE | ID: mdl-24648506

ABSTRACT

OBJECTIVES: Oral amoxicillin (50 mg/kg/day) thrice daily is the first-line therapy for non-severe childhood pneumonia. Compliance could be enhanced if two daily doses are employed. We assessed the equivalence of oral amoxicillin (50 mg/kg/day) thrice or twice daily in those patients. PATIENTS AND METHODS: This randomized (1 : 1), controlled, triple-blinded investigation conducted at one centre in Brazil included children aged 2-59 months with non-severe pneumonia diagnosed by trained paediatricians based on respiratory complaints and radiographic pulmonary infiltrate/consolidation. Participants were randomly assigned to receive one bottle (Amoxicillin 1) at 6 am, 2 pm and 10 pm and the other bottle (Amoxicillin 2) at 8 am and 8 pm: one bottle contained amoxicillin and the other placebo and vice versa. Only the pharmacist knew patients' allocation. Follow-up assessments were done at 2, 5 and 14 days after enrolment. Chest radiographs were read by three independent radiologists. Primary outcome was treatment failure (development of danger signs, persistence of fever, tachypnoea, development of serious adverse reactions, death and withdrawal from the trial) at 48 h. ClinicalTrials.gov: identifier NCT01200706. RESULTS: Four hundred and twelve and 408 participants received amoxicillin thrice or twice daily, respectively. Treatment failure was detected in 94 (22.8%) and 94 (23.0%) patients in intention-to-treat analysis (risk difference 0.2%; 95% CI: -5.5%-6.0%) and in 80 (20.1%) and 85 (21.3%) patients in per-protocol analysis (risk difference 1.2%; 95% CI: -4.4%-6.8%). Pneumonia was radiologically confirmed by concordant reading in 277 (33.8%) cases, among whom treatment failure was registered in 25/133 (18.8%) and 27/144 (18.8%) participants from the thrice and twice daily doses subgroups, respectively (risk difference -0.05%; 95% CI: -9.3%-9.2%). CONCLUSIONS: Oral amoxicillin (50 mg/kg/day) twice daily is as efficacious as thrice daily.


Subject(s)
Amoxicillin/administration & dosage , Anti-Bacterial Agents/administration & dosage , Pneumonia, Bacterial/drug therapy , Administration, Oral , Brazil , Child, Preschool , Female , Humans , Infant , Male , Treatment Outcome
14.
Open educational resource in Portuguese | CVSP - Brazil | ID: una-3536

ABSTRACT

A evolução da prática profissional da farmácia passou por diversas fases até o surgimento da atenção farmacêutica como prática profissional. É nesse sentido que esta Unidade começa sua abordagem, a qual resgata a prática clínica da farmácia e a evolução dos conceitos de atenção farmacêutica. Na lição seguinte o objetivo é que o aluno compreenda o que são os desfechos em saúde e sua relação com a qualidade da farmacoterapia e o processo de cuidado em saúde. Existem 3 principais desfechos: primordiais, intermediários e substitutos. Ainda nesta lição são apresentados os princípios da farmacoterapia ideal. Nesta Unidade o especializando irá conhecer os principais métodos de seguimento farmacoterapêutico utilizados para a documentação do cuidado farmacêutico: SOAP; PWDT; TOM; Dáder. Na sequência, o objetivo do conteúdo é que o estudante aplique o seguimento em um cenário real de atendimento ambulatorial. Sendo assim, ocorre a abordagem de demais temas que se fazem necessário para este "cenário" como o Acolhimento do usuário, coleta e organização de dados do usuário; Avaliação e identificação de problemas relacionados à farmacoterapi; Delineamento de um plano de cuidado em conjunto com o usuário e Seguimento individual do usuário. Por fim, o conteúdo descreve as condições de estrutura e processo necessárias para incorporação desta atividade na atenção primária à saúde.


Subject(s)
Health Management , Pharmaceutical Services , Pharmaceutical Services
15.
Int J Clin Pharm ; 35(4): 510-2, 2013 Aug.
Article in English | MEDLINE | ID: mdl-23794101

ABSTRACT

Asthma is a chronic inflammatory disorder of the airways that is characterized by recurrent symptoms associated with airflow limitation and by bronchial hyper-responsiveness. Free asthma treatment has been guaranteed in Brazil since 2003, notably after the Brazilian government decided to support drugs for the most serious forms of the disease. The asthma treatment access policy in Brazil offers a new opportunity for pharmacists to work closely with patients, and for caregivers and health care teams to promote educational activities and patient counselling about asthma. Pharmacists have an important role in the management of drug therapy within the health care team. Pharmacists should be prepared to engage with the latest concept of health care delivery proposed for Brazilian Unified Health System. These are centred on forming health care networks and strengthening multidisciplinary teams to integrate all professionals who are in charge of patient care.


Subject(s)
Anti-Asthmatic Agents/therapeutic use , Asthma/drug therapy , Health Services Accessibility , Pharmacists/organization & administration , Anti-Asthmatic Agents/economics , Anti-Asthmatic Agents/supply & distribution , Asthma/economics , Asthma/physiopathology , Brazil , Delivery of Health Care/organization & administration , Health Policy , Humans , Patient Care Team/organization & administration , Patient Education as Topic/methods , Pharmaceutical Services/organization & administration , Professional Role
16.
Am J Pharm Educ ; 77(4): 80, 2013 May 13.
Article in English | MEDLINE | ID: mdl-23716748

ABSTRACT

OBJECTIVE: To use a drug information center training module to teach evidence-based medicine to pharmacy students and to assess their satisfaction with the experience. DESIGN: During the 5-week module, students were taught how to develop information search strategies and to conduct critical analysis of scientific papers. The instructors developed activities based on past requests received by the university's Drug Information Center. The complexity of the assignments increased throughout the module. ASSESSMENT: One hundred twenty-one students were trained between August 2009 and July 2010. Sixty-seven (55.4%) completed a voluntary assessment form at the completion of the 5-week module. Students' feedback was positive, with 11 students suggesting that the module be integrated into the undergraduate curriculum. The most frequently (52.2%) mentioned area of dissatisfaction was with the performance of computers in the computer laboratory. CONCLUSIONS: The drug information center training module was an effective tool for teaching evidence-based medicine to pharmacy students. Additional research is needed to determine whether graduates are able to apply the knowledge and skills learned in the module to the pharmacy practice setting.


Subject(s)
Drug Information Services , Education, Pharmacy/methods , Evidence-Based Practice/education , Students, Pharmacy , Teaching/methods , Attitude of Health Personnel , Attitude to Computers , Computer-Assisted Instruction , Curriculum , Educational Technology , Feedback , Health Knowledge, Attitudes, Practice , Humans , Personal Satisfaction , Program Development , Program Evaluation , Students, Pharmacy/psychology , Surveys and Questionnaires
17.
Open educational resource in Portuguese | CVSP - Brazil | ID: una-615

ABSTRACT

A evolução da prática profissional da farmácia passou por diversas fases até o surgimento da atenção farmacêutica como prática profissional. É nesse sentido que esta Unidade começa sua abordagem, a qual resgata a prática clínica da farmácia e a evolução dos conceitos de atenção farmacêutica. Na lição seguinte o objetivo é que o aluno compreenda o que são os desfechos em saúde e sua relação com a qualidade da farmacoterapia e o processo de cuidado em saúde. Existem 3 principais desfechos: primordiais, intermediários e substitutos. Ainda nesta lição são apresentados os princípios da farmacoterapia ideal. Nesta Unidade o especializando irá conhecer os principais métodos de seguimento farmacoterapêutico utilizados para a documentação do cuidado farmacêutico: SOAP; PWDT; TOM; Dáder. Na sequência, o objetivo do conteúdo (Lição 4) é que o aluno aplique o seguimento em um cenário real de atendimento ambulatorial. Sendo assim, ocorre a abordagem de demais temas que se fazem necessário para este "cenário" como o Acolhimento do usuário, coleta e organização de dados do usuário; Avaliação e identificação de problemas relacionados à farmacoterapia; Delineamento de um plano de cuidado em conjunto com o usuário e Seguimento individual do usuário. Por fim, o conteúdo descreve as condições de estrutura e processo necessárias para incorporação desta atividade na atenção primária à saúde.


Subject(s)
Health Management , Pharmaceutical Services , Pharmaceutical Services
18.
Health Qual Life Outcomes ; 9: 91, 2011 Oct 25.
Article in English | MEDLINE | ID: mdl-22027368

ABSTRACT

BACKGROUND: Treatment with oral anticoagulant may influence the quality of life perception as it promotes changes in the patient's life, not offering an evident symptomatic relief and presenting well defined risks, such as bleeding. In this trial, the influence of chronic use of anticoagulants on the quality of life perception has been analyzed in patients assisted at the anticoagulation outpatient unit. METHODS: The health related quality of life was evaluated through a cross-section study with a sample composed of 72 patients seen from July 23, 2009 to September 2, 2010 at the Anticoagulation Outpatient Unit of the Federal University of Bahia's University Hospital. The study's population was composed by patients with atrial fibrillation and mechanical heart valve. The patients were submitted to two quality of life evaluation questionnaires: a generic questionnaire - the Medical Outcomes Study SF-36 Health Survey (SF36) - and a specific questionnaire - the Duke Anticoagulation Satisfaction Scale (DASS). RESULTS: The quality of life perception of the patients studied, based on both the DASS and the SF36, was positive regarding the treatment with oral anticoagulant. The SF36 presented an average score of 62.2 (± 20.0). Among the SF36 evaluated domains, the physical-emotional aspect was the most compromised one regarding life quality perception. The DASS presented an average score of 67.1 (± 18.2) and the domain presenting a greater compromise was the one related to the treatment inconveniences (annoyances, burdens and obligations). Previous hemorrhagic event, comorbidities, drug interactions with medicines that increase the anticoagulant effect, lower education level in the SF36 and younger age group influence a more negative perception of the quality of life, whereas lower education level in the DASS and the duration of treatment for more than 1 year offer a more positive perception. CONCLUSION: Patients seen at the anticoagulation outpatient unit of the University Hospital of Federal University of Bahia/Brazil had a positive perception of the treatment. Factors such as hemorrhagic event, comorbidities, drug interactions, education level, age group and duration of treatment have an influence on the quality of life perception.


Subject(s)
Anticoagulants/administration & dosage , Quality of Life , Administration, Oral , Adult , Aged , Aged, 80 and over , Atrial Fibrillation/prevention & control , Brazil , Cross-Sectional Studies , Female , Heart Valve Prosthesis , Humans , Male , Middle Aged , Observation , Surveys and Questionnaires
19.
Braz. j. pharm. sci ; 47(3): 643-649, July-Sept. 2011. tab
Article in English | LILACS | ID: lil-602683

ABSTRACT

Asthma is a chronic inflammatory disease of the airways that may lead to limitations in regular activities, to hospitalizations and a decrease in quality of life. Adherence to drug treatment is crucial for control of the disease. The use of medicinal herbs can reduce adherence to prescriptions, as the medication may be replaced by infusions or herbal products. The objective of this study was to evaluate the frequency of use of traditional herbal medicine among severe asthmatics in Salvador. Information on use of homemade remedies was obtained through application of a questionnaire during patient visits to a referral center. We also collected data on economic and social aspects as well as disease control. One hundred and forty-four (91,1 percent) out of one hundred and fifty-eight patients evaluated used herbal medicines, but only 26.5 percent attributed improvement of asthma symptoms to this alternative treatment and only 8 had substituted a prescribed medication by herbal medicines. There was a trend towards lower adherence to prescription drug treatment in this group of patients. Despite the high frequency of use of medicinal herbs in our sample, there was no improvement in the asthma treatment in this population compared to non-users. Adherence to conventional drug treatment was satisfactory and there was neither reduction in asthma control nor increase in hospitalizations among the users of medicinal plants.


A asma é uma enfermidade inflamatória crônica das vias aéreas que pode resultar em limitações nas atividades diárias, internações e prejuízo da qualidade de vida. A adesão ao tratamento medicamentoso é fundamental para o controle da doença. O uso de plantas medicinais pode reduzir a adesão ao tratamento prescrito, à medida que os medicamentos são substituídos por chás ou ervas. O objetivo deste estudo foi avaliar a frequência de uso de plantas medicinais entre asmáticos graves em Salvador. As informações sobre uso de remédios caseiros foram obtidas por meio de questionário durante a visita dos pacientes a um centro de referência. Foram coletados dados econômicos, sociais e de controle da doença. Cento e quarenta e quatro (91,1 por cento) dos cento e cinqüenta e oito pacientes avaliados utilizavam plantas medicinais, dos quais apenas 26,5 por cento atribuíam melhora dos sintomas da asma a este tratamento alternativo e somente 8 pacientes já haviam feito a substituição de medicamento por alguma planta medicinal. Houve tendência a menor adesão ao tratamento medicamentoso neste grupo de pacientes. Apesar da alta frequência do uso de plantas medicinais na nossa amostra, não houve melhora no tratamento da asma desta população em relação aos não-usuários. A adesão ao tratamento medicamentoso foi satisfatória, não havendo piora no controle da asma ou aumento em hospitalizações entre os usuários de plantas medicinais.


Subject(s)
Humans , Male , Female , Adult , Middle Aged , Asthma/therapy , Plants, Medicinal , Information Services/statistics & numerical data , Therapeutic Uses , Brazil/epidemiology , Cross-Sectional Studies , Medication Adherence , Surveys and Questionnaires
20.
Rev Assoc Med Bras (1992) ; 57(1): 42-5, 2011.
Article in Portuguese | MEDLINE | ID: mdl-21390458

ABSTRACT

OBJECTIVE: To determine the prevalence of hospital admissions due to ADR in Salvador, Bahia and their outcomes. METHODS: All patients admitted in four Sentinel Hospital (ANVISA) in Salvador-Ba were evaluated and followed to determine the prevalence of admissions due to ADR and their outcomes from April to December 2007. Cases were validated by 03 algorithms. The drugs were classified by Anatomical-Therapeutic-Chemical Classification, organs and systems affected by the WHO criteria and severity seconds Pearson et al. Type of ADR was analyzed by Rawlins and Thompson. RESULTS: The prevalence of ADR admission was 0.5% and adjusted for exposed was 2.1%, with 316 cases. Average of hospitalization due to ADR was 12.3 days. Younger and older accounted for 28.8% and 31.1% of patients. Females and blacks were 60% of cases. Main pharmacologic groups were antineoplastics, antibiotics and diuretics, affecting skin, gastrointestinal and hematologic systems. Around 70% of the ADR was validated as defined. ADR of type A was 80% and 90% recovered, and one death (0.5%). CONCLUSION: The prevalence of ADR admission was similar to those described in the literature and only one patient died. As this is the first national study will form the basis for future investigations.


Subject(s)
Adverse Drug Reaction Reporting Systems/statistics & numerical data , Drug-Related Side Effects and Adverse Reactions , Patient Admission/statistics & numerical data , Adolescent , Adult , Brazil , Child , Child, Preschool , Female , Humans , Infant , Infant, Newborn , Male , Middle Aged , Pharmacoepidemiology , Prospective Studies , Young Adult
SELECTION OF CITATIONS
SEARCH DETAIL
...